TABLE 2.

Comparison of the FOURIER and ODYSSEY Outcomes studies.

	FOURIER (Sabatine et al., 2017a)	ODYSSEY Outcomes (Schwartz et al., 2018)
Inclusion criteria	• Myocardial infarction, stroke, or peripheral artery disease and • LDL-C >70 mg/dL under statin therapy	• Acute coronary syndrome 1–12 months ago and • LDL-C >70 mg/dL under statin therapy
n =	• 27,564	• 18,924
Drug	• Evolocumab 140 mg every 2 weeks or 420 mg monthly	• Alirocumab 75 or 150 mg every 2 weeks • LDL-C target 25−50 mg/dL
LDL-C after 1 year of treatment	• 30 mg/dL	∙ 48 mg/dL
Primary endpoint	Composite of • cardiovascular death • myocardial infarction • non-hemorrhagic stroke • hospitalization for unstable angina • coronary revascularization	Composite of • coronary death • myocardial infarction • ischemic stroke • hospitalization for unstable angina
Median follow-up	• 2.2 years	• 2.8 years
Hazard ratio (95% confidence interval) for the primary endpoint	• 0.85 (0.79–0.92)	• 0.85 (0.78–0.93)

Abbreviation: LDL-C, low-density lipoprotein cholesterol.